FR20C1030I2 - Inhibiteurs de beta-lactamase - Google Patents

Inhibiteurs de beta-lactamase

Info

Publication number: FR20C1030I2
Authority: FR; France
Prior art keywords: beta; lactamase inhibitors; lactamase; inhibitors
Prior art date: 2008-01-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR20C1030C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Organon Pharma UK Ltd

Merck Sharp and Dohme LLC

Original Assignee

Merck Sharp and Dohme Ltd

Merck Sharp and Dohme LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-18

Filing date

2020-07-10

Publication date

2021-08-27

2020-02-10 Publication of FR20C1030I1 publication Critical patent/FR20C1030I1/fr

2020-07-10 Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd

2021-08-27 Application granted granted Critical

2021-08-27 Publication of FR20C1030I2 publication Critical patent/FR20C1030I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrrole Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

FR20C1030C 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase Active FR20C1030I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1153308P	2008-01-18	2008-01-18
PCT/US2009/031047 WO2009091856A2 (fr)	2008-01-18	2009-01-15	Inhibiteurs de bêta-lactamase

Publications (2)

Publication Number	Publication Date
FR20C1030I1 FR20C1030I1 (fr)	2020-02-10
FR20C1030I2 true FR20C1030I2 (fr)	2021-08-27

Family

ID=40642204

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
FR20C1030C Active FR20C1030I2 (fr)	2008-01-18	2020-07-10	Inhibiteurs de beta-lactamase
FR20C1031C Active FR20C1031I2 (fr)	2008-01-18	2020-07-10	Inhibiteurs de beta-lactamase
FR20C1032C Active FR20C1032I2 (fr)	2008-01-18	2020-07-10	Inhibiteurs de beta-lactamase

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
FR20C1031C Active FR20C1031I2 (fr)	2008-01-18	2020-07-10	Inhibiteurs de beta-lactamase
FR20C1032C Active FR20C1032I2 (fr)	2008-01-18	2020-07-10	Inhibiteurs de beta-lactamase

Country Status (38)

Country	Link
US (2)	US8487093B2 (fr)
EP (2)	EP2666774B1 (fr)
JP (3)	JP5038509B2 (fr)
KR (2)	KR101648728B1 (fr)
CN (2)	CN101918407B (fr)
AU (1)	AU2009206119C1 (fr)
BR (1)	BRPI0906871B1 (fr)
CA (1)	CA2712783C (fr)
CO (1)	CO6331438A2 (fr)
CR (1)	CR11626A (fr)
CY (5)	CY1114900T1 (fr)
DK (2)	DK2231667T3 (fr)
DO (1)	DOP2010000218A (fr)
EC (2)	ECSP10010345A (fr)
ES (2)	ES2433744T3 (fr)
FR (3)	FR20C1030I2 (fr)
HN (1)	HN2010001395A (fr)
HR (2)	HRP20131123T1 (fr)
HU (2)	HUS000513I2 (fr)
IL (1)	IL206395A (fr)
LT (3)	LTC2231667I2 (fr)
LU (1)	LUC00165I2 (fr)
MA (1)	MA32025B1 (fr)
ME (1)	ME02089B (fr)
MX (1)	MX2010007823A (fr)
MY (1)	MY162532A (fr)
NI (1)	NI201000115A (fr)
NL (2)	NL301051I2 (fr)
NO (3)	NO2020022I1 (fr)
NZ (1)	NZ586861A (fr)
PL (2)	PL2666774T3 (fr)
PT (2)	PT2231667E (fr)
RS (2)	RS53862B1 (fr)
RU (1)	RU2445314C9 (fr)
SI (2)	SI2231667T1 (fr)
UA (1)	UA101966C2 (fr)
WO (1)	WO2009091856A2 (fr)
ZA (1)	ZA201005333B (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2231667T1 (sl) *	2008-01-18	2013-12-31	Merck Sharp & Dohme Corp.	Beta laktamazni inhibitorji
BR112013003045B1 (pt)	2010-08-10	2021-08-31	Rempex Pharmaceuticals, Inc.	Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
US8772490B2 (en) *	2010-12-22	2014-07-08	Meiji Seika Pharma Co., Ltd.	Optically active diazabicyclooctane derivatives and process for preparing the same
CN104892490B (zh) *	2010-12-22	2017-07-21	明治制果药业株式会社	用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物
WO2012172368A1 (fr) *	2011-06-17	2012-12-20	Astrazeneca Ab	Procédé de préparation de composés hétérocycliques, notamment le trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide et ses sels
KR101512738B1 (ko) *	2011-08-27	2015-04-17	욱크하르트 리미티드	1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
JP5677634B2 (ja)	2011-08-30	2015-02-25	ウォックハートリミテッド	１，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
US9012491B2 (en)	2011-08-31	2015-04-21	Rempex Pharmaceuticals, Inc.	Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9505761B2 (en)	2011-12-02	2016-11-29	Fedora Pharmaceuticals Inc.	Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en)	2011-12-02	2014-08-05	Naeja Pharmaceutical Inc.	Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
AU2013207510A1 (en)	2012-01-06	2014-07-31	The Regents Of The University Of California	Compositions, methods of use, and methods of treatment
US8969570B2 (en) *	2012-03-30	2015-03-03	Cubist Pharmaceuticals, Inc.	Beta-lactamase inhibitors
US8916709B2 (en)	2012-03-30	2014-12-23	Cubist Pharmaceuticals, Inc.	1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
SG11201406120SA (en) *	2012-03-30	2014-10-30	Cubist Pharm Inc	ISOXAZOLE β-LACTAMASE INHIBITORS
MX2014011827A (es) *	2012-03-30	2015-02-20	Cubist Pharm Inc	Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa.
AR090539A1 (es)	2012-04-02	2014-11-19	Astrazeneca Ab	COMPUESTOS INHIBIDORES DE b LACTAMASA
WO2013169725A2 (fr)	2012-05-08	2013-11-14	Codexis, Inc.	Biocatalyseurs et procédés pour l'hydroxylation de composés chimiques
US9156858B2 (en)	2012-05-23	2015-10-13	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
UA117734C2 (uk)	2012-05-30	2018-09-25	Мейдзі Сейка Фарма Ко., Лтд.	НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ
US10561675B2 (en)	2012-06-06	2020-02-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (pt) *	2012-08-25	2020-04-14	Wockhardt Ltd	derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
US20150315145A1 (en) *	2012-11-01	2015-11-05	Kaneka Corporation	Process for producing optically active bicyclic urea compound
KR102147420B1 (ko) *	2012-12-07	2020-08-25	베나토알엑스 파마슈티컬스, 인크.	베타-락타마제 억제제
UA111925C2 (uk) *	2012-12-11	2016-06-24	Федора Фармасьютікалз Інк.	БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
MX2015008627A (es)	2013-01-04	2015-09-23	Rempex Pharmaceuticals Inc	Derivados de acido boronico y usos terapeuticos de los mismos.
US9241947B2 (en)	2013-01-04	2016-01-26	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en)	2013-01-04	2015-08-11	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (fr)	2013-01-04	2014-07-10	Rempex Pharmaceuticals, Inc.	Derives d'acide boronique et leurs utilisations therapeutiques
WO2014110442A1 (fr)	2013-01-10	2014-07-17	VenatoRx Pharmaceuticals, Inc.	Inhibiteurs de bêta-lactamase
CN105143224A (zh) *	2013-03-08	2015-12-09	沃克哈特有限公司	一种制备(2s,5r)-硫酸单-{[(4-氨基哌啶-4-基)羰基]-7-氧代-1,6-二氮杂-双环[3.2.1]-辛-6-基}酯的方法
AU2013380573B2 (en) *	2013-03-08	2016-07-07	Wockhardt Limited	A process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
CN105143225A (zh)	2013-03-08	2015-12-09	沃克哈特有限公司	一种制备(2s,5r)-7-氧代-6-磺酰氧基-2-[((3r)-哌啶-3-羰基)-肼基羰基]-1,6-二氮杂-双环[3.2.1]辛烷的方法
WO2014135931A1 (fr) *	2013-03-08	2014-09-12	Wockhardt Limited	Procédé pour la préparation du (2s, 5r)-7-oxo-6-sulfo-oxy-2-[((3r)-pipéridine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
KR101774132B1 (ko)	2013-03-08	2017-09-01	욱크하르트 리미티드	(2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
US9624222B2 (en) *	2013-03-08	2017-04-18	Wockhardt Limited	Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octance
US9120795B2 (en)	2013-03-14	2015-09-01	Cubist Pharmaceuticals, Inc.	Crystalline form of a β-lactamase inhibitor
EP2970340B1 (fr)	2013-03-14	2020-02-12	Venatorx Pharmaceuticals, Inc.	Inhibiteurs de bêta-lactamase
AU2014278556B2 (en) *	2013-06-10	2018-07-19	Merck Sharp & Dohme Llc	Preparation of tert-butyl 4-((1R,2S,5R)-6- (benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2- carboxamido)piperidine-1-carboxylate
MY176278A (en)	2013-09-24	2020-07-27	Meiji Seika Pharma Co Ltd	Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (fr) *	2013-10-02	2015-04-09	Cubist Pharmaceuticals, Inc.	Sel picoline inhibiteur de b-lactamase
NZ757221A (en)	2013-10-08	2021-12-24	Meiji Seika Pharma Co Ltd	Crystalline forms of diazabicyclooctane derivative and production process thereof
WO2015079329A2 (fr) *	2013-11-26	2015-06-04	Wockhardt Limited	Procédé de préparation de (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-méthyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
ES2719136T3 (es)	2014-03-24	2019-07-08	Novartis Ag	Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
WO2015150891A1 (fr) *	2014-03-29	2015-10-08	Wockhardt Limited	Procédé de préparation de mono-[2-(5-azétidin-3-ylméthyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]ester d'acide sulfurique trans
WO2015150890A1 (fr) *	2014-03-29	2015-10-08	Wockhardt Limited	Procédé de préparation de mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl}ester d'acide sulfurique trans
US9687497B1 (en)	2014-05-05	2017-06-27	Rempex Pharmaceuticals, Inc.	Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RS59488B1 (sr)	2014-05-05	2019-12-31	Rempex Pharmaceuticals Inc	Sinteza boronatnih soli i njihove upotrebe
KR20170007448A (ko)	2014-05-19	2017-01-18	렘펙스 파머수티클스 인코퍼레이티드	보론산 유도체 및 그의 치료적 용도
KR102396753B1 (ko)	2014-06-11	2022-05-12	베나토알엑스 파마슈티컬스, 인크.	베타-락타마제 억제제
US9511142B2 (en)	2014-06-11	2016-12-06	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
EP3164406B1 (fr)	2014-07-01	2024-12-25	Qpex Biopharma, Inc.	Dérivés d'acide boronique et leurs utilisations thérapeutiques
SI3221313T1 (sl)	2014-11-17	2019-04-30	Entasis Therapeutics Limited	Kombinacijska terapija za zdravljenje okužb z rezistentnimi bakterijami
WO2016081297A1 (fr)	2014-11-18	2016-05-26	Rempex Pharmaceuticals, Inc.	Dérivés d'esters d'acide boronique cycliques et leurs utilisations thérapeutiques
WO2016089718A1 (fr)	2014-12-02	2016-06-09	Merck Sharp & Dohme Corp.	Procédé pour la préparation de 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)-pipéridine-1-carboxylate de tert-butyle et ses analogues
BR112017010445B8 (pt)	2014-12-05	2024-02-27	Meiji Seika Pharma Co Ltd	Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
US20180051041A1 (en)	2015-03-17	2018-02-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US10570131B2 (en)	2015-03-31	2020-02-25	Mutabilis	Heterocyclic compounds and their use in preventing or treating bacterial infections
MX2017014080A (es) *	2015-05-07	2018-07-06	Mutabilis	Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EP3347008B1 (fr)	2015-09-11	2022-03-09	Venatorx Pharmaceuticals, Inc.	Inhibiteurs de bêta-lactamases
EP3281942A4 (fr) *	2015-09-16	2018-08-15	Xuanzhu Pharma Co., Ltd.	Inhibiteur de ss-lactamase et son application
CN108137567A (zh)	2015-10-02	2018-06-08	乐高化学生物科学股份有限公司	用于抑制β-内酰胺酶的组合物和方法
WO2017100537A1 (fr)	2015-12-10	2017-06-15	VenatoRx Pharmaceuticals, Inc.	Inhibiteurs de bêta-lactamases
EP3386982A1 (fr) *	2015-12-11	2018-10-17	The Wockhardt Limited	Composés contenant du 7-oxo-6-(sulfo-oxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation dans le traitement d'infections bactériennes
US10472345B2 (en)	2016-02-04	2019-11-12	Merck Sharp & Dohme Corp.	Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
CN108778270B (zh) *	2016-03-31	2021-07-30	吉林四环制药有限公司	一种抗菌组合物及其用途
WO2017213758A1 (fr)	2016-06-09	2017-12-14	Codexis, Inc.	Biocatalyseurs et procédés d'hydroxylation de composés chimiques
US10294249B2 (en)	2016-06-30	2019-05-21	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (fr)	2016-08-04	2018-02-08	VenatoRx Pharmaceuticals, Inc.	Composés contenant du bore
SMT202200397T1 (it) *	2016-09-16	2022-11-18	Entasis Therapeutics Ltd	Composti inibitori di beta-lattamasi
EP3515915B1 (fr) *	2016-09-19	2021-08-04	Merck Sharp & Dohme Corp.	Procédé de préparation d'intermédiaires d'hydroxyurée inhibiteurs des bêta-lactamases
JOP20190061A1 (ar) *	2016-09-28	2019-03-26	Novartis Ag	مثبطات بيتا-لاكتاماز
CN108078982B (zh) *	2016-11-21	2020-02-07	天津大学	脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
PL3592362T3 (pl)	2017-03-06	2025-06-23	VenatoRx Pharmaceuticals, Inc.	Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania
CN108619141B (zh) *	2017-03-16	2021-09-10	山东轩竹医药科技有限公司	一种抗菌组合物及其用途
CN110709081B (zh)	2017-05-08	2023-09-22	恩塔西斯治疗公司	用于治疗细菌感染的化合物及方法
US10085999B1 (en)	2017-05-10	2018-10-02	Arixa Pharmaceuticals, Inc.	Beta-lactamase inhibitors and uses thereof
US11267826B2 (en)	2017-05-26	2022-03-08	VenatoRx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
US11332485B2 (en)	2017-05-26	2022-05-17	VenatoRx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
SG11202000217QA (en)	2017-07-21	2020-02-27	Antabio Sas	Chemical compounds
CN109568323B (zh) *	2017-09-29	2022-09-30	吉林四环制药有限公司	抗菌组合物及其用途
US11286270B2 (en)	2017-10-11	2022-03-29	Qpex Biopharma, Inc.	Boronic acid derivatives and synthesis thereof
EP3719020B1 (fr)	2017-12-01	2022-09-21	Qilu Pharmaceutical Co., Ltd.	Forme cristalline d'un inhibiteur de beta-lactamase et son procédé de préparation
CN109956941B (zh) *	2017-12-25	2020-08-04	新发药业有限公司	一种阿维巴坦的简便制备方法
EP3744722A4 (fr)	2018-01-25	2021-11-03	Suzhou Sinovent Pharmaceuticals Co., Ltd.	INHIBITEUR DE ß-LACTAMASE ET SON UTILISATION
EP3781576B1 (fr)	2018-04-20	2024-06-12	Qpex Biopharma, Inc.	Dérivés d'acide boronique et leurs utilisations thérapeutiques
EP3572411A1 (fr)	2018-05-21	2019-11-27	Antabio SAS	Dérivés de thiazole comme inhibiteurs de métallo-bêta-lactamases
WO2019226931A1 (fr)	2018-05-25	2019-11-28	VenatoRx Pharmaceuticals, Inc.	Inhibiteurs de protéine de liaison à la pénicilline
US11905286B2 (en)	2018-08-09	2024-02-20	Antabio Sas	Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (fr) *	2018-12-18	2020-06-24	Antabio SAS	Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases
EP3833665B1 (fr) *	2018-08-09	2023-07-19	Antabio SAS	Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases
US11897844B2 (en) *	2018-09-21	2024-02-13	Api Corporation	Method for producing amino acid derivatives
WO2020072442A1 (fr) *	2018-10-01	2020-04-09	Arixa Pharmaceuticals, Inc.	Dérivés de relebactam et utilisations associées
CN111072660B (zh) *	2018-10-22	2021-05-18	新发药业有限公司	一种瑞来巴坦的简便制备方法
SG11202108905UA (en)	2019-03-12	2021-09-29	Arixa Pharmaceuticals Inc	Crystalline form of an avibactam derivative
CN114206851B (zh)	2019-04-26	2025-02-11	默沙东有限责任公司	可用于制备(2s,5r)-7-氧代-n-哌啶-4-基-6-(硫酸基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的中间体的制备方法
JP7647110B2 (ja) *	2020-01-22	2025-03-18	日油株式会社	ポリエーテルエステル化合物
EP4146650A4 (fr)	2020-09-01	2024-01-17	Ningxia Academy of Agriculture and Forestry Sciences	Inhibiteurs de bêta-lactamase et leur préparation
WO2022047790A1 (fr) *	2020-09-07	2022-03-10	Ningxia Academy Of Agriculture And Forestry Sciences	Composés bicycliques substitués par amidine, leur préparation, leur utilisation comme agents antibactériens et inhibiteurs de bêta-lactamase
CN111943950B (zh) *	2020-09-10	2022-03-29	山东安信制药有限公司	一种瑞来巴坦的制备方法
EP4146651A4 (fr)	2021-05-07	2024-06-05	Ningxia Academy of Agriculture and Forestry Sciences	Composés substitués de sulfonylamidine et leur utilisation en tant qu'inhibiteurs de bêta-lactamase
US11814385B2 (en) *	2021-06-25	2023-11-14	University Of South Florida	Small molecule inhibitors targeting Clostridioides difficile sporulation
US20250302846A1 (en) *	2022-05-11	2025-10-02	The Regents Of The University Of Colorado A Body Corporate	Antibiotic composition and methods of use thereof
CN117384169B (zh) *	2022-07-05	2025-10-17	福安药业集团重庆三禾兴医药科技有限公司	一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途
GB202306833D0 (en)	2023-05-09	2023-06-21	Adjutec Pharma As	Therapy
GB202306826D0 (en)	2023-05-09	2023-06-21	Adjutec Pharma As	Therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4616038A (en)	1978-07-24	1986-10-07	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4880793A (en)	1978-07-24	1989-11-14	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US5071843A (en)	1978-07-24	1991-12-10	Merck & Co., Inc.	Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4539208A (en)	1980-09-17	1985-09-03	Merck & Co., Inc.	Combination of thienamycin-type antibiotics with dipeptidase inhibitors
ES2090393T3 (es)	1991-04-11	1996-10-16	Hoffmann La Roche	Beta-lactamas.
CZ282567B6 (cs)	1993-12-29	1997-08-13	Pfizer Inc.	Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
JP3199300B2 (ja) *	1994-05-09	2001-08-13	三共株式会社	１−メチルカルバペネム誘導体
DE69623497T2 (de)	1995-12-21	2003-05-28	Sankyo Co., Ltd.	1-methylcarbapenem-derivate
JP2965922B2 (ja) *	1995-12-21	1999-10-18	三共株式会社	１−メチルカルバペネム誘導体
JP2955276B2 (ja) *	1997-06-19	1999-10-04	三共株式会社	１−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) *	1998-03-19	2010-06-30	富山化学工業株式会社	５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
JP4226818B2 (ja)	1999-07-06	2009-02-18	メチルジーン・インコーポレーテッド	ベータ−ラクタマーゼのスルフォンアミドメチルホスホン酸阻害剤
WO2001010834A2 (fr)	1999-08-10	2001-02-15	British Biotech Pharmaceuticals Limited	Agents antibacteriens
FR2812635B1 (fr) *	2000-08-01	2002-10-11	Aventis Pharma Sa	Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2002212182A (ja) *	2000-11-16	2002-07-31	Sankyo Co Ltd	１−メチルカルバペネム誘導体
ES2273902T3 (es)	2000-11-16	2007-05-16	Sankyo Company, Limited	Derivados de 1-metilcarbapenem.
FR2825705B1 (fr)	2001-06-08	2005-05-20	Aventis Pharma Sa	Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) *	2002-01-28	2006-10-20	Aventis Pharma Sa	Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) *	2002-05-15	2004-02-12	Sankyo Co Ltd	１−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) *	2002-12-06	2008-10-21	Novexel	Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
CN1845897A (zh) *	2003-07-09	2006-10-11	帕拉特克药品公司	取代的四环素化合物
US6984652B2 (en)	2003-09-05	2006-01-10	Warner-Lambert Company Llc	Gyrase inhibitors
JP2008502583A (ja)	2003-10-01	2008-01-31	バイエル・ヘルスケア・アクチェンゲゼルシャフト	抗細菌性アミド大員環
WO2005082050A2 (fr)	2004-02-24	2005-09-09	Ssci, Inc.	Analyse et criblage de formes solides au moyen de la fonction de distribution de paires atomiques
SI1965798T1 (sl) *	2005-12-07	2012-01-31	Basilea Pharmaceutica Ag	Uporabni monobaktamski antibiotiki
US20100009957A1 (en)	2006-09-27	2010-01-14	Blizzard Timothy A	Novel inhibitors of beta-lactamase
SI2231667T1 (sl) *	2008-01-18	2013-12-31	Merck Sharp & Dohme Corp.	Beta laktamazni inhibitorji

2009
- 2009-01-15 SI SI200930777T patent/SI2231667T1/sl unknown
- 2009-01-15 SI SI200931147T patent/SI2666774T1/sl unknown
- 2009-01-15 UA UAA201010164A patent/UA101966C2/ru unknown
- 2009-01-15 ES ES09701487T patent/ES2433744T3/es active Active
- 2009-01-15 CA CA2712783A patent/CA2712783C/fr active Active
- 2009-01-15 PL PL13180969T patent/PL2666774T3/pl unknown
- 2009-01-15 RU RU2010134425/04A patent/RU2445314C9/ru active
- 2009-01-15 EP EP13180969.1A patent/EP2666774B1/fr active Active
- 2009-01-15 WO PCT/US2009/031047 patent/WO2009091856A2/fr not_active Ceased
- 2009-01-15 PT PT97014872T patent/PT2231667E/pt unknown
- 2009-01-15 ME MEP-2013-511A patent/ME02089B/fr unknown
- 2009-01-15 KR KR1020107015963A patent/KR101648728B1/ko active Active
- 2009-01-15 MY MYPI2010003255A patent/MY162532A/en unknown
- 2009-01-15 US US12/812,763 patent/US8487093B2/en active Active
- 2009-01-15 DK DK09701487.2T patent/DK2231667T3/da active
- 2009-01-15 KR KR1020167021668A patent/KR101800610B1/ko active Active
- 2009-01-15 NZ NZ586861A patent/NZ586861A/en unknown
- 2009-01-15 EP EP09701487.2A patent/EP2231667B1/fr active Active
- 2009-01-15 PL PL09701487T patent/PL2231667T3/pl unknown
- 2009-01-15 CN CN200980102425.0A patent/CN101918407B/zh active Active
- 2009-01-15 BR BRPI0906871-6A patent/BRPI0906871B1/pt active IP Right Grant
- 2009-01-15 MX MX2010007823A patent/MX2010007823A/es active IP Right Grant
- 2009-01-15 JP JP2010543219A patent/JP5038509B2/ja active Active
- 2009-01-15 DK DK13180969.1T patent/DK2666774T3/en active
- 2009-01-15 ES ES13180969.1T patent/ES2533826T3/es active Active
- 2009-01-15 HR HRP20131123AT patent/HRP20131123T1/hr unknown
- 2009-01-15 RS RS20150154A patent/RS53862B1/sr unknown
- 2009-01-15 AU AU2009206119A patent/AU2009206119C1/en active Active
- 2009-01-15 PT PT131809691T patent/PT2666774E/pt unknown
- 2009-01-15 RS RS20130511A patent/RS53052B/sr unknown
- 2009-01-15 CN CN201210277503.4A patent/CN102827067B/zh active Active
2010
- 2010-06-15 IL IL206395A patent/IL206395A/en active IP Right Grant
- 2010-06-30 NI NI201000115A patent/NI201000115A/es unknown
- 2010-07-12 HN HN2010001395A patent/HN2010001395A/es unknown
- 2010-07-15 EC EC2010010345A patent/ECSP10010345A/es unknown
- 2010-07-16 DO DO2010000218A patent/DOP2010000218A/es unknown
- 2010-07-16 MA MA33026A patent/MA32025B1/fr unknown
- 2010-07-21 CO CO10088709A patent/CO6331438A2/es active IP Right Grant
- 2010-07-27 ZA ZA2010/05333A patent/ZA201005333B/en unknown
- 2010-08-10 CR CR11626A patent/CR11626A/es unknown
- 2010-10-26 EC EC2010010568A patent/ECSP10010568A/es unknown
2011
- 2011-05-26 JP JP2011118249A patent/JP5597164B2/ja active Active
2012
- 2012-05-22 JP JP2012116243A patent/JP5422020B2/ja active Active
2013
- 2013-06-06 US US13/911,549 patent/US20130274475A1/en not_active Abandoned
- 2013-12-03 CY CY20131101079T patent/CY1114900T1/el unknown
2015
- 2015-03-10 HR HRP20150269TT patent/HRP20150269T1/hr unknown
- 2015-03-23 CY CY20151100288T patent/CY1116243T1/el unknown
2020
- 2020-06-25 NL NL301051C patent/NL301051I2/nl unknown
- 2020-06-25 NL NL301050C patent/NL301050I2/nl unknown
- 2020-06-30 LU LU00165C patent/LUC00165I2/fr unknown
- 2020-07-03 LT LTPA2020516C patent/LTC2231667I2/lt unknown
- 2020-07-03 LT LTPA2020518C patent/LTC2666774I2/lt unknown
- 2020-07-03 LT LTPA2020517C patent/LTPA2020517I1/lt unknown
- 2020-07-09 HU HUS2000023C patent/HUS000513I2/hu unknown
- 2020-07-09 HU HUS2000024C patent/HUS000504I2/hu unknown
- 2020-07-10 FR FR20C1030C patent/FR20C1030I2/fr active Active
- 2020-07-10 FR FR20C1031C patent/FR20C1031I2/fr active Active
- 2020-07-10 FR FR20C1032C patent/FR20C1032I2/fr active Active
- 2020-07-15 CY CY2020025C patent/CY2020025I1/el unknown
- 2020-07-15 CY CY2020023C patent/CY2020023I2/el unknown
- 2020-07-15 CY CY2020024C patent/CY2020024I1/el unknown
- 2020-08-10 NO NO2020022C patent/NO2020022I1/no unknown
- 2020-08-10 NO NO2020023C patent/NO2020023I1/no unknown
- 2020-08-10 NO NO2020024C patent/NO2020024I1/no unknown

Also Published As

Publication number	Publication date
CY2020023I1 (el)	2020-11-25
UA101966C2 (en)	2013-05-27
NO2020024I1 (no)	2020-08-10
US20110294777A1 (en)	2011-12-01
FR20C1031I2 (fr)	2022-07-29
FR20C1032I2 (fr)	2022-07-29
NO2020022I1 (no)	2020-08-10
EP2231667A2 (fr)	2010-09-29
DK2231667T3 (da)	2013-12-16
NO2020023I1 (no)	2020-08-10
CN102827067B (zh)	2015-09-23
AU2009206119C1 (en)	2016-05-26
CA2712783C (fr)	2013-03-19
CY2020024I2 (el)	2020-11-25
CY2020023I2 (el)	2020-11-25
IL206395A (en)	2015-04-30
CN102827067A (zh)	2012-12-19
KR20160099117A (ko)	2016-08-19
LTPA2020517I1 (lt)	2020-07-27
ES2433744T3 (es)	2013-12-12
KR20100130176A (ko)	2010-12-10
JP2011510012A (ja)	2011-03-31
EP2231667B1 (fr)	2013-09-04
MX2010007823A (es)	2010-08-10
WO2009091856A2 (fr)	2009-07-23
DK2666774T3 (en)	2015-03-23
IL206395A0 (en)	2010-12-30
CY2020025I2 (el)	2020-11-25
ECSP10010568A (es)	2010-11-30
HN2010001395A (es)	2012-11-12
KR101800610B1 (ko)	2017-11-23
KR101648728B1 (ko)	2016-08-17
LTPA2020516I1 (lt)	2020-07-27
AU2009206119B2 (en)	2012-06-07
EP2666774A1 (fr)	2013-11-27
LTPA2020518I1 (lt)	2020-07-27
JP2011207900A (ja)	2011-10-20
HUS2000024I1 (hu)	2021-03-29
WO2009091856A3 (fr)	2009-12-03
LTC2666774I2 (lt)	2022-01-25
PL2231667T3 (pl)	2014-01-31
FR20C1030I1 (fr)	2020-02-10
FR20C1032I1 (fr)	2020-02-10
RU2445314C1 (ru)	2012-03-20
CY1116243T1 (el)	2017-03-15
CY2020024I1 (el)	2020-11-25
ME02089B (fr)	2014-04-30
HRP20131123T1 (hr)	2013-12-20
MY162532A (en)	2017-06-15
BRPI0906871A2 (pt)	2020-07-28
CN101918407A (zh)	2010-12-15
LUC00165I2 (fr)	2021-08-16
JP2012214475A (ja)	2012-11-08
JP5597164B2 (ja)	2014-10-01
RS53862B1 (sr)	2015-08-31
US8487093B2 (en)	2013-07-16
PL2666774T3 (pl)	2015-06-30
RU2445314C9 (ru)	2013-04-10
US20130274475A1 (en)	2013-10-17
NL301051I2 (nl)	2020-09-03
NI201000115A (es)	2011-07-08
HK1186180A1 (en)	2014-03-07
CA2712783A1 (fr)	2009-07-23
HUS000504I2 (hu)	2021-03-29
CY1114900T1 (el)	2016-12-14
FR20C1031I1 (fr)	2020-02-10
MA32025B1 (fr)	2011-01-03
NL301050I2 (nl)	2020-09-03
EP2666774B1 (fr)	2015-01-07
PT2231667E (pt)	2013-12-13
SI2231667T1 (sl)	2013-12-31
CO6331438A2 (es)	2011-10-20
HUS2000023I1 (hu)	2021-03-29
CY2020025I1 (el)	2020-11-25
HUS000513I2 (hu)	2021-03-29
DOP2010000218A (es)	2010-08-31
PT2666774E (pt)	2015-04-13
ECSP10010345A (es)	2010-08-31
SI2666774T1 (sl)	2015-04-30
JP5038509B2 (ja)	2012-10-03
LTC2231667I2 (lt)	2021-07-26
HK1143809A1 (en)	2011-01-14
HRP20150269T1 (hr)	2015-04-24
RS53052B (sr)	2014-04-30
CN101918407B (zh)	2014-02-26
ZA201005333B (en)	2011-04-28
CR11626A (es)	2010-09-13
NZ586861A (en)	2011-12-22
ES2533826T3 (es)	2015-04-15
JP5422020B2 (ja)	2014-02-19
AU2009206119A1 (en)	2009-07-23
BRPI0906871B1 (pt)	2021-09-28

Publication	Publication Date	Title
FR20C1030I2 (fr)	2021-08-27	Inhibiteurs de beta-lactamase
CY2017016I1 (el)	2017-07-12	Αναστολεις πρωτεασωματος
BRPI0917808A2 (pt)	2019-09-24	inibidores de cmet
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0807547A2 (pt)	2014-06-17	Inibidores de aspartil protease hetercíclicos
BRPI0918564A2 (pt)	2015-12-01	inibidores
BRPI0810365A2 (pt)	2014-10-29	Inibidores de mlc-1 de indol 7-substituído
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
BRPI0806898A2 (pt)	2015-07-14	Inibidores de mek
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
EP2374802A4 (fr)	2012-06-20	Inhibiteur de production de kynurénine
EP2467382A4 (fr)	2013-01-02	Inhibiteurs de pde10 d amino-tétrahydro-pyridopyrimidine
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
EP2435048A4 (fr)	2013-07-10	Inhibiteurs de pde10 radio-marqués
DK2240506T3 (da)	2013-04-08	IAP inhibitorer
BRPI0918966A2 (pt)	2015-12-01	inibidores de protease
BRPI0912564A2 (pt)	2019-09-24	inibidores de jnk
ATE522533T1 (de)	2011-09-15	Pyrazolopyrimidinonkinaseinhibitor
BRPI0919073A2 (pt)	2016-03-15	inibidores de protease
FI20075320A0 (fi)	2007-05-07	Uusia käyttökelpoisia inhibiittoreita
FI20080062A0 (fi)	2008-01-28	Työkalu
ATE529422T1 (de)	2011-11-15	3-indazolyl-4-pyridylisothiazole
AT10428U3 (de)	2009-08-15	Sport-stock